PolynovoASX:PNV +1.07%76 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:PNV with a GF Score™ of 76/100 and a GF Value™ of A$3.24 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Polynovo ranks better than 65.73% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Polynovo's Net Income for the
six
months ended in Dec. 2025 was A$0.0 Mil. Polynovo's Revenue for the
six
months ended in Dec. 2025 was A$70.2 Mil. Therefore, Polynovo's net margin for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for Polynovo's Net Margin % or its related term are showing as below:
ASX:PNV'
s Net Margin % Range Over the Past 10 Years
Min: -138.36 Med: -17.36 Max: 10.38
Current: 7.16
ASX:PNV's Net Margin % is ranked better than 65.73% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs ASX:PNV: 7.16
Polynovo (ASX:PNV) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Polynovo Net Margin % Related Terms
Polynovo Net Margin % Historical Data
* Premium members only.
The historical data trend for Polynovo's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Net Margin % distribution charts can be found below:
* The bar in red indicates where Polynovo's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (ASX:PNV) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #280 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 34.3%.
Is Polynovo's Net Margin % too high?
Polynovo's current Net Margin % is 0.00%. Based on the distribution chart, Polynovo ranks #280 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Polynovo has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #280 out of 817 companies for Net Margin %. This puts Polynovo in the upper half of its industry. The industry median Net Margin % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (ASX:PNV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$3.24, compared to a current price of A$0.95 — trading 70.8% below its estimated fair value. The current Net Margin % is 0.00%. Polynovo's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Polynovo (ASX:PNV), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (ASX:PNV) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of A$0.95 is trading 70.8% below its estimated GF Value™ of A$3.24.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for ASX:PNV:
Net Margin %: 0.00%
GF Value™: A$3.24 vs. price of A$0.95 (70.8% below fair value)
No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
76GF Score
Get the complete analysis for ASX:PNV
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PNV has been successfully added to your 
